111 Inc. (YI) stock prices closed the trading day on September 3rd, 2021 at USD$6.56, the same price it opened at. Subsequent current market fluctuations saw the stock surge by 5.95%, bringing it up to USD$6.95.
YI Stock Invests in Growth
The second quarter of fiscal 2021 saw YI stock continue investing in the development of its industry-leading technology. The company reported a 186% year-over-year increase in technology expenses, which accounted for 1.7% of net revenues for Q2 2021. This is comparable to the 1.1% of net revenues reported in the prior-year quarter. the company’s increased investments in technology yielded results, facilitating the obtaining of a total of 18 patients for its internally-developed proprietary technology in areas of digital health, big data analytics, and SMART supply chain technology.
YI Stock’s 1 Clinic Solution
The company’s cutting-edge technology solutions serve to support their internal efficient supply chain infrastructure. The solutions also enable customers to better serve their customers using the company’s SaaS enterprise solutions, which is particularly beneficial for pharmacies in YI stock’s network. Furthermore, the company has continued to cater to healthcare providers with more innovative solutions. This includes 1 Clinic, which offers e-hospital service and seamlessly connects patients with appropriate doctors through its digital solutions. This makes the platform very attractive for pharmaceutical companies that are seeking to launch and commercialize new drugs in China.
Network of Partnerships
YI stock has commenced various partnerships with several pharmaceutical companies that are seeking to leverage the company’s technology and network to commercialize their products. Partners include Eli Lily’s Trulicity, Taltz, and Verzenio, with a focus on treating diabetes, severe plaque psoriasis, and metastatic breast cancer. The company has also partnered with Novartis’ Consentyx for the treatment of plaque psoriasis, as well as Sanofi’s Dupixent, for the treatment of Eczema.
Share Repurchase Program
September 7th, 2021 saw YI stock announce a share repurchase program which authorizes the company to repurchase up to USD$10 million of its Class A ordinary shares. These purchases will be in the form of American Depositary Shares (ADS) over the course of the next 12 months.
Future Outlook for YI Stock
The company reported a promising end to the first half of fiscal 2021, as evidenced by the strength of its financial reports for Q2 2021. YI stock is poised to capitalize on the opportunities afforded to is as a result of its growing network of partnerships. Current and potential investors are hopeful that management will be able to facilitate significant and sustained increases in shareholder value over the long term.
